Project Grant R44AI186932
Award Date
8/8/24
Completion Date
7/31/25
Dollars Obligated
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Orlance, Inc. (KH6YJYH55G53)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98104, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Scripps Research Institute to develop a broad-spectrum influenza vaccine. The goal of the project is to target the neuraminidase (NA) protein, which is engaged by broadly neutralizing antibodies that can provide protection against diverse influenza strains. The research will evaluate recently discovered NA broadly neutralizing...
This $390,942 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a universal influenza vaccine using self-assembled peptide nanoparticles (SAPNs). The key goals are to: Assemble and characterize SAPNs functionalized with highly conserved influenza antigens, including the hemagglutinin stalk (HRHA) and matrix protein 2 ectodomain (4M2E), on the external surface, and...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories), a woman-owned small business located in Ann Arbor, Michigan. The purpose of this award is to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. This...
This Cooperative Agreement award, valued at $1,195,056.00 and granted by the National Institute of Allergy and Infectious Diseases (NIAID), supports research under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to leverage machine learning and computational tools to develop broadly protective influenza vaccines that can elicit long-lasting immunity. Key objectives include: 1) designing germline-targeting immunogens that target conserved epitopes on the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,969 Project Grant to L2 Diagnostics LLC under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to evaluate a mosquito salivary protein, AGBR1, as a potential vaccine candidate against Chikungunya virus, an arboviral disease transmitted by infected mosquitoes. The project aims to conduct comparative assessments of different AGBR1 vaccine formulations, including...
This Cooperative Agreement award, valued at $1,246,617.00 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop computational models that can accurately predict the breadth and durability of influenza vaccine responses. The key objectives are to: Capture existing influenza vaccine data and generate new experimental data connecting immunological variables with vaccine outcomes....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...
This $2,074,701 federal Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to advance understanding of the biological and physical drivers of influenza A virus (IAV) transmission in humans. Key objectives include: Defining the dynamics of viral load, immune responses, and infectious aerosol production in humans infected with seasonal IAV using a controlled...
This $3,878,480 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by HDT Bio Corp to develop innovative RNA-based vaccine technologies. The primary focus is on characterizing the immunological function of skeletal muscle dendritic cells, understanding how type I interferon signaling limits transgene expression and adaptive immune responses, and investigating the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $668,569.00 to characterize and optimize a novel genetic vaccine platform called PARVAX. The key objectives are to: Investigate the mechanism behind the potency and durability of the PARVAX platform, hypothesized to be correlated with antigen expression kinetics. Use rational engineering approaches to enhance...